Related Experiment Video

Updated: Aug 21, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Celecoxib: a novel treatment for lung cancer

Hussein Abou-Issa1, Galal Alshafie

  • 1Ohio State University, Division of Surgical Oncology, Department of Surgery, College of Medicine & Public Health, M-260 Starling-Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA. abou-issa.1@osu.edu

Expert Review of Anticancer Therapy
|October 16, 2004
PubMed

Insights

Novel lung cancer treatments are needed. Celecoxib, a cyclooxygenase (COX)-2 inhibitor, shows promise in enhancing chemotherapy and radiation therapy response, offering a new therapeutic avenue for lung cancer patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lung cancer remains a leading cause of cancer mortality with limited therapeutic advancements.
  • Cyclooxygenase (COX)-2 is implicated in cancer pathogenesis, presenting a potential therapeutic target.
  • Selective COX-2 inhibitors, like celecoxib, are anti-inflammatory agents with potential anticancer applications.

Purpose of the Study:

  • To review the therapeutic potential of celecoxib in lung cancer treatment.
  • To examine the evidence supporting celecoxib's role in enhancing conventional lung cancer therapies.

Main Methods:

  • Review of preclinical and clinical data on celecoxib in lung cancer.
  • Analysis of celecoxib's mechanism of action, including its effects on COX-2 pathways.
  • Evaluation of celecoxib's efficacy and safety profile in solid tumors.

Main Results:

  • Celecoxib, a selective COX-2 inhibitor, is generally well-tolerated with minimal toxicity.
  • Phase II trials suggest celecoxib enhances responses to chemotherapy and radiation therapy.
  • Celecoxib demonstrates antitumor efficacy in various solid tumors dependent on COX-2.

Conclusions:

  • Celecoxib exhibits promising antitumor activity and may enhance conventional treatments for lung cancer.
  • Targeting COX-2 with celecoxib represents a viable strategy for improving lung cancer outcomes.
  • Further investigation into celecoxib's role in lung cancer therapy is warranted.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.